CN104491149A - Medicine for treating senile cataract - Google Patents
Medicine for treating senile cataract Download PDFInfo
- Publication number
- CN104491149A CN104491149A CN201410826738.3A CN201410826738A CN104491149A CN 104491149 A CN104491149 A CN 104491149A CN 201410826738 A CN201410826738 A CN 201410826738A CN 104491149 A CN104491149 A CN 104491149A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- senile cataract
- liver
- treating senile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating senile cataract. The medicine is prepared from the following medicinal raw materials in parts by weight: 10 parts of radix rehmanniae preparata, 9 parts of mulberries, 15 parts of chrysanthemum and 6 parts of angelica sinensis. In light of treatment experience learned from family, the inventor understands main ideas of dissertations of ancient books and records, combines the pathological study of modern medicine on ophthalmic diseases and summarizes the invention for treating senile cataract. In the formula, radix rehmanniae preparata belonging to liver and kidney channels has the functions of enriching blood and nourishing yin and replenishing essence and benefiting marrow; mulberries belonging to liver and kidney channels have the functions of nourishing yin and enriching blood, engendering liquid and moistening dryness and lubricating the intestines and detoxifying; chrysanthemum belonging to liver channel has the functions of dispelling wind, clearing away heat, improving eyesight and detoxifying; and angelica sinensis which is warm in nature has the function of promoting blood circulation to remove blood stasis. As the medicines are combined in use for treating senile cataract, the medicine provided by the invention substantially achieves the condition that as the medicine takes effect, the symptoms lessens.
Description
Technical field
The present invention relates to a kind of medicine, be specifically related to a kind of Chinese medicine being used for the treatment of senile cataract.
Background technology
Senile senile cataract (senile cataract) is one of modal height morbidity of old people, occupy first of senile oculopathy, senile cataract is equivalent to traditional Chinese medical science cataract, be also called " cataract, nuclear cataract, incipient cataract, cataract " etc., primary disease mostly occurs more than 40 years old, "Nei Jing" is carried: " year to four ten, half of YIN QI consumed." visible old asthenia, cloudy insufficiency of essence, affecting ophthalmic crystal metabolism is the main cause that cataract generates.To its treatment to nourish liver.Kidney, beneficial intensive culture blood are main points, and in addition, stagnated heat of liver channel or the deficiency of YIN are attacked on holding under the arm and wetting, and prolonged illness causes the stasis of blood, and crystal loses supports, and the turbid stasis of blood is then raw also can cause primary disease.Understanding is in a word that deficiency in origin has relation with mark is real, but deficiency in origin outbalance, prompting prevents and treats senile cataract and wants nourishing the liver and kidney, blood circulation promoting and blood stasis dispelling.
According to TCM Ophthalmology principle of " convincing opinion by patient analysis ", then effectively can eliminate three through causing stasis, passages through which vital energy circulates must be unimpeded from convincing by patient analysis, recover the keeping of its vital essence blood, and our major function is nourishing the liver and kidney, blood circulation promoting and blood stasis dispelling, modern pharmacological research, Radix Rehmanniae Preparata, Fructus Mori, Flos Chrysanthemi, Periostracum Cicadae flower improve the activity of ocular tissue SOD, obviously extend the time-to-live of deficiency of YIN mice normobaric hypoxia, can resist vitamin E and consume excessively, delay radical damage process, NO content and MDA can also be made to reduce, there is certain elimination oxygen-derived free radicals, delay ocular tissue's aging and wait effect.Modern pharmacological research, with blood stasis dispelling class medicine, can increase the activity of fibrinoclase, and expansion peripheral vessels, improves microcirculation, stops Cataractogenesis, impels muddy absorption of crystal.
Medical material involved in the present invention is all recorded in " Chinese Pharmacopoeia ".
Summary of the invention
The present invention aims to provide a kind of medicine being used for the treatment of senile cataract, by selecting suitable medical material and proportioning thereof, reaches the safe and effective object being applied to senile cataract treatment.
In order to achieve the above object, the present invention is by the following technical solutions:
Be used for the treatment of a medicine for senile cataract, it is characterized in that, it is prepared from by the raw medicinal material of following weight proportion: 10 parts, Radix Rehmanniae Preparata, Fructus Mori 9 parts, Flos Chrysanthemi 15 parts, Radix Angelicae Sinensis 6 parts.
Inventor, according to the Couple herbs had the deep influence of a scholarly family, understands the main idea that ancient books and records are discussed, and in conjunction with the pathological study of modern medicine to ophthalmic diseases, sums up the present invention, in order to treat senile cataract.In side, Radix Rehmanniae Preparata returns liver, kidney channel, yin nourishing of enriching blood, life essence-filling, marrow-benefitting; Fructus Mori return liver, kidney channel, nourishing YIN and supplementing blood, promote the production of body fluid moisturize, intestine moistening toxin expelling; Flos Chrysanthemi returns Liver Channel, dispelling wind, heat clearing away, improving eyesight, removing toxic substances; Radix Angelicae Sinensis, warm in nature, blood circulation promoting and blood stasis dispelling.All medicines share, and treatment senile cataract, can accomplish that As the medicine took effect, the symptoms lessened substantially.
Below in conjunction with clinical laboratory data, beneficial effect of the present invention is described:
1, object and method
Inventor collects 110 routine patients altogether during in July, 2012 in June, 2013, and patient dependence is all good, can follow up a case by regular visits to check.
1.1 include case standard in
1. " the practical ophthalmology " that meet People's Health Publisher's publication in 1984 diagnoses basic standard.2. overall health of patients is good, estimates more than 5-year Survival.3. age >=45 years old ,≤70 years old person.4. outpatient is main.5. senile cataract at the immature stage lenticular opacity calibration: I: vision 0.5 ~ 0.8, crystalline lens is that haze or a small amount of cloud sheet shape are muddy, and optical fundus is clear.II: vision 0.1 ~ 0.4, the lamellar muddiness that crystalline lens is more, optical fundus is slightly fuzzy.
1.2 physical data
In 110 routine patients, man 50 example, female 60 example, at minimum 53 years old of age, maximum 80 years old, the course of disease was the shortest 3 months, the longest nearly 7 years.Be divided into treatment group and each 55 examples of matched group at random, compare physical data there was no significant difference, there is comparability for two groups.
2, research method
2.1 Therapeutic Method
Treatment group takes the decoct that the present invention obtains according to specific embodiment 1, and every bu morning, noon and afternoon take for three times.
Matched group uses BAINEITING DIYANYE (Wuhan Yuanda Pharmaceutical Group Co., Ltd.'s production), uses according to its description.
All treat 3 months for two groups.
2.2 statistical method
Adopt SPSS18.0 statistics software data processing.
3, therapeutic outcome
3.1 criterion of therapeutical effect
1. effective: after the course for the treatment of, vision improves more than 3 row on the original basis.Lenticular opacity degree becomes dust-like by lamellar, and granule is comparatively thin, and makes muddy absorption over half.
2. effective: after the course for the treatment of, to improve 1-2 on the original basis capable for vision.Lenticular opacity degree is changed to graininess by lamellar, muddy incomplete absorption half.
3. invalid: after the course for the treatment of, vision is without enhancement, lenticular opacity degree is without change.
4. cure: after the course for the treatment of, vision is recovered completely.
Total effective rate=(cure+effective+effectively) total number of cases × 100% of ÷.
3.2 liang of group curative effects
The visible treatment group effective percentage of result significantly better than matched group, in table 1.
Table 1 liang group comparitive study
| Group | n | Cure | Effective | Effectively | Invalid | Total effective rate |
| Treatment group | 55 | 24 | 16 | 11 | 4 | 92.7％* |
| Matched group | 55 | 15 | 11 | 17 | 12 | 78.2％ |
Compare with matched group, * P < 0.05 compares matched group.
3.3 untoward reaction
Over the course for the treatment of, there is blurred vision 4 example in matched group to patient, treatment group has no obvious adverse reaction.
Visible, the medicine that the present invention obtains can safe and effective treatment senile cataract, has good medical science promotional value.
Detailed description of the invention
In order to understand better and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment.
Embodiment 1
Take: 10 parts, Radix Rehmanniae Preparata, Fructus Mori 9 parts, Flos Chrysanthemi 15 parts, Radix Angelicae Sinensis 6 parts; Add 8 times of water gagings, decoct 1.5 hours, filter; Filtering residue adds 6 times of water gagings, decocts 1 hour, filters; Merging filtrate, is concentrated into 120 grams, must meet the decoct of adult normal's one day consumption.
Be used for the treatment of senile cataract.Oral, every bu morning, noon and afternoon take for three times.
Embodiment 2
Take: 10 parts, Radix Rehmanniae Preparata, Fructus Mori 9 parts, Flos Chrysanthemi 15 parts, Radix Angelicae Sinensis 6 parts; Add 10 times of water gagings, decoct 2 hours, filter; Filtering residue adds 8 times of water gagings, decocts 1.5 hours, filters; Merging filtrate, concentrated, dry, packaging, must meet the powder of adult normal's one day consumption.
Be used for the treatment of senile cataract.Oral, daily once.
Embodiment 3
Take: 10 parts, Radix Rehmanniae Preparata, Fructus Mori 9 parts, Flos Chrysanthemi 15 parts, Radix Angelicae Sinensis 6 parts; Add 6 times of water gagings, decoct 3 times, each decoction 1 hour, merges decoction liquor, concentrated, dry, incapsulates shell, must meet the capsule of adult normal's one day consumption.
Be used for the treatment of senile cataract.Oral, every bu is taken for twice sooner or later.
Claims (1)
1. be used for the treatment of a medicine for senile cataract, it is characterized in that, it is prepared from by the raw medicinal material of following weight proportion: 10 parts, Radix Rehmanniae Preparata, Fructus Mori 9 parts, Flos Chrysanthemi 15 parts, Radix Angelicae Sinensis 6 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410826738.3A CN104491149A (en) | 2014-12-18 | 2014-12-18 | Medicine for treating senile cataract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410826738.3A CN104491149A (en) | 2014-12-18 | 2014-12-18 | Medicine for treating senile cataract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104491149A true CN104491149A (en) | 2015-04-08 |
Family
ID=52932663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410826738.3A Pending CN104491149A (en) | 2014-12-18 | 2014-12-18 | Medicine for treating senile cataract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104491149A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943693A (en) * | 2006-10-17 | 2007-04-11 | 宝鸡市瑞海药业有限责任公司 | Traditional Chinese medicine preparation for eye health care and asthenopia alleviation |
| CN1973873A (en) * | 2006-12-12 | 2007-06-06 | 中国人民解放军第三军医大学 | Eye health food capsule |
| CN101972340A (en) * | 2010-10-08 | 2011-02-16 | 张继成 | Traditional Chinese medicine composition for tonifying liver and improving eyesight |
| CN102178784A (en) * | 2011-04-20 | 2011-09-14 | 威海康博尔生物药业有限公司 | Combination therapy used for treating visual disturbances and damages and relieving asthenopia |
| CN103720888A (en) * | 2012-10-15 | 2014-04-16 | 钱国祥 | Abalone shell health wine used for cataract |
| CN104013506A (en) * | 2014-06-09 | 2014-09-03 | 曾庆芸 | Operating room nursing device |
-
2014
- 2014-12-18 CN CN201410826738.3A patent/CN104491149A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943693A (en) * | 2006-10-17 | 2007-04-11 | 宝鸡市瑞海药业有限责任公司 | Traditional Chinese medicine preparation for eye health care and asthenopia alleviation |
| CN1973873A (en) * | 2006-12-12 | 2007-06-06 | 中国人民解放军第三军医大学 | Eye health food capsule |
| CN101972340A (en) * | 2010-10-08 | 2011-02-16 | 张继成 | Traditional Chinese medicine composition for tonifying liver and improving eyesight |
| CN102178784A (en) * | 2011-04-20 | 2011-09-14 | 威海康博尔生物药业有限公司 | Combination therapy used for treating visual disturbances and damages and relieving asthenopia |
| CN103720888A (en) * | 2012-10-15 | 2014-04-16 | 钱国祥 | Abalone shell health wine used for cataract |
| CN104013506A (en) * | 2014-06-09 | 2014-09-03 | 曾庆芸 | Operating room nursing device |
Non-Patent Citations (2)
| Title |
|---|
| 孙熠等: "年龄相关性白内障的中医药治疗", 《国际眼科杂志》 * |
| 谭秋元: "活血祛障汤治疗老年性白内障200例疗效观察", 《湖南中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101732506B (en) | External oculentum for treating amblyopia, astigmatism, strabismus, myopia and visual fatigue of teenagers | |
| CN101524513B (en) | Health pillow drug core | |
| CN101474330B (en) | Antidiarrheal oral liquid and technique for preparing the same | |
| CN102813798B (en) | Preparation method of traditional Chinese medicine for treating heat toxicity-type acute glomerulonephritis | |
| CN102670993B (en) | Traditional Chinese medicine for treating cataract | |
| CN102198227B (en) | Method for preparing Chinese medicine for treating yin-deficiency glaucoma | |
| CN102805820A (en) | Method for preparing traditional Chinese medicine for treating cough type acute glomerulonephritis | |
| CN102793902B (en) | Preparation method for traditional Chinese medicine used for treatment of kidney and yin deficient type acute glomerulonephritis | |
| CN104491149A (en) | Medicine for treating senile cataract | |
| CN102793903B (en) | Preparation method of Chinese medicament for treating kidney-yang deficiency type acute glomerulonephritis | |
| CN102813757B (en) | Preparation method of traditional Chinese medicine for treating lumbago type acute glomerulonephritis | |
| CN102813837B (en) | Preparation method of traditional Chinese medicine for treating blood pressure rising type acute glomerulonephritis | |
| CN102579986A (en) | Chinese medicinal pain-removing mixture for treating migraine | |
| CN103099968A (en) | Preparation method of traditional Chinese medicine for treating keratitis caused by fire excess from yin deficiency | |
| CN102784320B (en) | Preparation method of traditional Chinese medicine for treating urine color yellow turbidity type acute glomerulonephritis | |
| CN102813848B (en) | Preparation method of traditional Chinese medicine for treating vomit type acute glomerulonephritis | |
| CN102813771A (en) | Preparation method of traditional Chinese medicine for treating hydroncus type acute glomerulonephritis | |
| CN102805853B (en) | Preparation method of traditional Chinese medicine for treating proteinuria type acute glomerulonephritis | |
| CN102813895B (en) | Preparation method of traditional Chinese medicine for treating somnolence-type acute glomerulonephritis | |
| CN105250394A (en) | Traditional Chinese medicine composition for treating cataract and preparation method and application thereof | |
| CN104257890A (en) | Traditional Chinese medicine healthcare preparation for clearing lung and internal heat | |
| CN102813785A (en) | Preparation method of traditional Chinese medicine for treating headache-type acute glomerulonephritis | |
| CN102961608A (en) | Traditional Chinese medicine for treating liver-yang hyperactivity type vertigo | |
| CN102813822A (en) | Preparation method of traditional Chinese medicine for treating pain type acute glomerulonephritis | |
| CN109517705A (en) | Maonan's tincture and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150408 |
|
| RJ01 | Rejection of invention patent application after publication |